Cytochalasin B (Phomin) (Synonyms: NSC 107658, Phomin) |
| Catalog No.GC32890 |
Cytochalasin B (Phomin)는 세포를 통과할 수 있는 묵균독소이며, 이는 Phoma 속에 속하는 자낭균으로부터 분리되었다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14930-96-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cytochalasin B (Phomin)는 세포를 통과할 수 있는 묵균독소이며, 이는 Phoma 속에 속하는 자낭균으로부터 분리되었다. Cytochalasin B는 직접적으로 세포골격 단백질의 중합에 직접적인 영향을 미쳐 액틴 마이크로파일러메트의 형성을 억제할 수 있다. F-actin의 빠르게 성장하는 쪽에 결합하고 덧셈단백질과 상호작용하여 액틴 마이크로파일러메트의 핵생장-연장 과정에 영향을 미친다[3-4].
Cytochalasin B (0.1-10 µM; 0-72시간)는 용량 의존적으로 hASCs의 대사, 증식, 형태에 영향을 미치고 액틴 마이크로파일러메트의 점진적인 해체와 관련이 있다[5]. Cytochalasin B는 여러 종류의 세포에서 DNA 조각화를 유도할 수 있다[6]. Cytochalasin B (10-8-10-1M; 24-96시간)는 용량과 시간에 따라 U251 세포 증식을 효과적으로 억제한다. Cytochalasin B는 용량 의존적으로 G2/M 단계의 세포 비율을 증가시켜 미토틱 인덱스를 증가시키고 CDC2 및 cyclin B1 단백질 수준을 낮운다[7].
Cytochalasin B(Cytochalasin B는 2% 카르복시메틸 셀룰로오스 1% 트윈 20 (CMC/Tw)의정지 형태로 준비됐다; 장내 주사; 10, 25, 또는 50 mg/kg; 8일)는 용량 의존적으로 P388/ADR 백혈병을 앓고 있는 Balb/c 쥐의 수명을 연장시킨다[8]. Cytochalasin B(5 µg/ml Cytochalasin B; 30분)는 쥐 알기뇨세포에 대한내 정자 주입(ICSI) 중에 처리되어 발아율을 증가시키며, 발육에 지장을 주지 않는다[9].
References:
[1]. Van Goietsenoven G, Mathieu V, et,al. In vitro growth inhibitory effects of cytochalasins and derivatives in cancer cells. Planta Med. 2011 May;77(7):711-7. doi: 10.1055/s-0030-1250523. Epub 2010 Nov 5. PMID: 21058241.
[2]. Trendowski M. Using cytochalasins to improve current chemotherapeutic approaches. Anticancer Agents Med Chem. 2015;15(3):327-35. doi: 10.2174/1871520614666141016164335. PMID: 25322987; PMCID: PMC4485394.
[3]. MacLean-Fletcher S, Pollard TD. Mechanism of action of cytochalasin B on actin. Cell. 1980 Jun;20(2):329-41. doi: 10.1016/0092-8674(80)90619-4. PMID: 6893016.
[4]. Flanagan MD, Lin S. Cytochalasins block actin filament elongation by binding to high affinity sites associated with F-actin. J Biol Chem. 1980 Feb 10;255(3):835-8. PMID: 7356663.
[5]. Bianconi E, Tassinari R, et,al. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629. PMID: 35626666; PMCID: PMC9139657.
[6]. Kolber MA, Broschat KO, et,al. Cytochalasin B induces cellular DNA fragmentation. FASEB J. 1990 Sep;4(12):3021-7. doi: 10.1096/fasebj.4.12.2394319. PMID: 2394319.
[7]. Tong ZG, Liu N, et,al. Cytochalasin B inhibits the proliferation of human glioma U251 cells through cell cycle arrest and apoptosis. Genet Mol Res. 2014 Dec 19;13(4):10811-22. doi: 10.4238/2014.December.19.2. PMID: 25526201.
[8]. Trendowski M, Mitchell JM, et,al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. doi: 10.1007/s10637-014-0203-5. Epub 2015 Jan 7. PMID: 25563824; PMCID: PMC4387261.
[9].Hu LL, Shen XH, et,al. Cytochalasin B treatment of mouse oocytes during intracytoplasmic sperm injection (ICSI) increases embryo survival without impairment of development. Zygote. 2012 Nov;20(4):361-9. doi: 10.1017/S0967199411000438. Epub 2011 Aug 15. PMID: 21838963.
| 세포 실험 [1]: | |
세포 라인 | 인간 간충적 간세포 (hMSCs) |
제조 방법 | 세포는 Cytochalasin B나 0.05% DMSO가 존재하는 조건하에서 재배되었습니다. |
반응 조건 | 0.1-10 µM; 0-72 시간 동안 |
응용 분야 | Cytochalasin B는 용량 의존적으로hASCs의 대사, 증식 및 형태에 영향을 미쳤습니다. |
| 동물 실험 [2]: | |
동물 모형 | Balb/c 쥐 (P388/ADR 백혈병을 가진) |
제조 방법 | 쥐 (P388/ADR 백혈병)는 1일부터 8일까지 Cytochalasin B를 투여되었습니다. |
제형 | Cytochalasin B는 2% 카르복시메틸 셀룰로오스 1% 트윈 20(CMC/Tw)에서 정지 형태로 준비되었습니다 ; 배강 주사(i.p.); 10, 25, 또는 50mg/kg; 8일 동안 |
응용 분야 | Cytochalasin B는 P388/ADR 백혈병을 가진 Balb/c 쥐의 예상 수명을 용량 의존적으로 증가시킵니다. |
참고문헌: [1]. Bianconi E, Tassinari R, et,al. Cytochalasin B Modulates Nanomechanical Patterning and Fate in Human Adipose-Derived Stem Cells. Cells. 2022 May 12;11(10):1629. doi: 10.3390/cells11101629. PMID: 35626666; PMCID: PMC9139657.[2].Trendowski M, Mitchell JM, et,al. Chemotherapy with cytochalasin congeners in vitro and in vivo against murine models. Invest New Drugs. 2015 Apr;33(2):290-9. doi: 10.1007/s10637-014-0203-5. Epub 2015 Jan 7. PMID: 25563824; PMCID: PMC4387261. | |
| Cas No. | 14930-96-2 | SDF | |
| Synonyms | NSC 107658, Phomin | ||
| Canonical SMILES | O=C1N[C@@H](CC2=CC=CC=C2)[C@@]3([H])[C@]14[C@](/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(O4)=O)([H])[C@H](O)C([C@H]3C)=C | ||
| Formula | C29H37NO5 | M.Wt | 479.61 |
| Solubility | DMF: 30 mg/ml DMF:PBS (pH 7.2) (1:20): 0.05 mg/ml DMSO: 20 mg/ml Ethanol: 20 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.085 mL | 10.4251 mL | 20.8503 mL |
| 5 mM | 0.417 mL | 2.085 mL | 4.1701 mL |
| 10 mM | 0.2085 mL | 1.0425 mL | 2.085 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *